These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 29423758)

  • 41. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
    Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
    Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
    Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
    Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.
    Zhao XS; Liu YR; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Han W; Sun YQ; Yan CH; Mo XD; Wang YZ; Fan QZ; Wang XY; Liu KY; Huang XJ; Chang YJ
    Am J Hematol; 2019 May; 94(5):512-521. PubMed ID: 30680765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
    Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
    Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
    Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
    Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
    Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT.
    Chen J; Labopin M; Pabst T; Zhang X; Jiang E; Tucci A; Cornelissen J; Meijer E; Khevelidze I; Polge E; Wu D; Mohty M; Gorin NC
    Bone Marrow Transplant; 2023 Dec; 58(12):1322-1330. PubMed ID: 37640797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD
    Pandya BJ; Burns LJ; Wang T; Xie B; Touya M; Spalding J; Block A; Kuperman G; Young C
    Transplant Cell Ther; 2024 Jul; 30(7):683.e1-683.e13. PubMed ID: 38663769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management.
    Taylor E; Morris K; Ellis M; Marlton P; Baveshi K; Clarey J; Irving I; Cochrane T; Kennedy G
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):426-430. PubMed ID: 29383835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.
    Zhang YY; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Liu KY; Huang XJ
    Bone Marrow Transplant; 2019 Sep; 54(9):1462-1470. PubMed ID: 30710101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
    Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
    Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
    Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
    Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M;
    Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
    Schiller GJ; Tuttle P; Desai P
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
    Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.